<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468153</url>
  </required_header>
  <id_info>
    <org_study_id>Ruijin-CAR-01</org_study_id>
    <nct_id>NCT03468153</nct_id>
  </id_info>
  <brief_title>Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma</brief_title>
  <official_title>The Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with relapsed or refractory lymphoma often develop resistance to chemotherapy.
      Chimeric antigen receptor-modified T cell (CART) therapy showed promising effect in B-cell
      malignancies these years. CD19 and CD22 are proteins expressed on the surface of the lymphoma
      cells in patients with CD19+CD22+ lymphoma. The CAR enables the T-cells to recognize and kill
      the tumor cell through recognition of CD19 and CD22. This is a phase 2 trial to study the
      safety and efficacy of dual specificity CD19 and CD22 CAR-T cell immunotherapy for CD19+CD22+
      relapsed and refractory lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall remission rate</measure>
    <time_frame>4 weeks after infusion</time_frame>
    <description>Rate of complete remission and patial remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse toxicity</measure>
    <time_frame>Day 0, day 4, week 1, week 3, week 4, month 2, month 12 after CAR-T cells were infused</time_frame>
    <description>According to CTCAE 4.0 criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>CAR-T cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient-derived dual specificity CD19 and CD22 CAR-T</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy</intervention_name>
    <description>Patient-derived dual specificity CD19 and CD22 CAR-T Cells</description>
    <arm_group_label>CAR-T cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological detection confirmed CD19/CD22 postive lymphoma;

          -  Recieved more than 2 lines of chemotherapy;

          -  Not eligible for hematopoietic stem cell transplantation or relapsed after
             hematopoietic stem cell transplantation;

          -  Life expectation for more than 3 months;

          -  ECOG ≥ 2;

          -  Adequate organ function: EF≥50%; normal ECG; CCR≥40ml/min; ALT and AST ≤ 3 × upper
             limitation of normal, T-BIL ≤ 2.0mg/dl; PT and APTT &lt; 2 × upper limitation of normal;
             SpO2 &gt; 92%;

          -  CBC results: Hb ≥ 80g/L, ANC &gt; 1 × 10E9/L, Plt ≥ 50 × 10E9/L;

          -  Results of pregnant test should be negative, and agree to conception control during
             treatment and 1 year after CAR-T infusion;

          -  With measurable disease;

          -  Written informed consent could be acquired;

        Exclusion Criteria:

          -  Immunosuppressive agents or steroids in recent 1 week before recruitment;

          -  Uncontrolled infection;

          -  HIV positive ;

          -  Active HBV or HCV infection;

          -  Women in pregnancy and lactation;

          -  Refuse to conception control during treatment and 1 year after CAR-T infusion;

          -  Uncured malignancies other than non-Hodgkin lymphoma;

          -  Have participated similar trial for treating relapse/refractory non-Hodgkin lymphoma;

          -  Inheritated immune deficiancy;

          -  Severe heart disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weili Zhao, MD</last_name>
    <phone>64370045</phone>
    <phone_ext>610707</phone_ext>
    <email>zhao.weili@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weili Zhao, MD</last_name>
      <phone>64370045</phone>
      <phone_ext>610707</phone_ext>
      <email>zhao.weili@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2018</study_first_submitted>
  <study_first_submitted_qc>March 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Weili</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

